Adamis drug flunks COVID trial
 

Today's Big News

Sep 21, 2022
 
 

After various reports highlighted a shortage for Moderna’s new bivalent omicron booster, it seems production issues at a Catalent plant were at the center of the problem. But Moderna expects “availability constraints” to be resolved soon. 

Adamis’ sole clinical-stage asset, Tempol, has failed a study in COVID-19, triggering a steep share-price decline. But CEO David Marguglio maintained that the company is “bullish” about the prospects for its two approved drugs. 

After increasing its stake in specialty pharmacy company Shields Health Solutions last year, Walgreens is ready to buy out the rest of the firm. Along with news of the purchase, Walgreens revealed a pair of exec moves. - Eric Sagonowsky

 
 

Featured

 
 

Moderna's new booster launch tripped up by production issues at Catalent plant: reports

After quietly withholding millions of Moderna’s newly formulated COVID-19 booster doses because of manufacturing issues at a Catalent factory in Indiana, the United States has released the shots. The news comes after unexplained supply problems with the Moderna booster, which was authorized for use by the FDA on Aug. 31.
 
 
 
 
 

Top Stories

 
 

Adamis’ shares nosedive as sole clinical-stage asset flunks COVID-19 trial

Another COVID-19 therapy bites the dust. This time it’s Adamis Pharmaceuticals’ failed phase 2/3 trial for antiviral Tempol, triggering a 44% drop in its share price.
 
 
 

Walgreens to acquire remaining stake in Shields Health for $1.37B, announces exec moves

Walgreens Boots Alliance said it will buy the remaining stake in Shields Health Solutions for approximately $1.37 billion after a 2021 purchase of 71% of the pharmacy company's stock. The transaction is expected to be completed by the end of the year.
 
 
 

Medtronic, ReCor tee off renal denervation data showing cuts in high blood pressure

Designed to disrupt overactive nerve signals from the blood vessels surrounding the kidneys, two major players put forward data this week showing their devices could make a dent in hypertension.
 
 
 

Bay State biotechs Sesen and Carisma blend together in bid to transform cancer treatment

Sesen Bio and privately held Carisma Therapeutics are merging, with plans to combine into a “well-funded” biotech that will operate under the name Carisma and work to advance engineered macrophages for cancer treatment.
 
 
 

Cash-depleted Acerus undergoes strategic review to stay afloat

Sexual-health-focused Acerus says it's undergoing a strategic review to find new financial options. The company reported less than $2 million in cash on hand at the end of the second quarter.
 
 
 

Diabeloop’s insulin delivery AI boosts time in range, minimizes hypoglycemia in one-year data

Diabeloop has developed an AI algorithm that, true to the French startup’s name, promises to close the diabetes management loop by connecting insulin pumps and continuous glucose monitors and completely automating the entire insulin delivery process.
 
 
 
 
 

Resources

 
 

Make the most out of hybrid conferences

Improve your congress competitive intelligence and cut down costs by 50%

 
 
 

Leading lab instruments provider saves $2M a year

How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers

 
 
 

Achieving faster formulation for First In Human supplies

Supporting your product development programme through experience, expertise, and efficiency.

 
 
 

The Hands-Free, Low-Volume, Microfluidic Elisa Alternative

Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume.

 
 
 

Optimize Digital Engagement Across the Patient Journey

Improve patient engagement, adherence, and outcomes
 
 
 

Improve Life Sciences Research with AI Workflow Automation

Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster?
 
 
 

Building a Broader Tissue Research Ecosystem

Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue.
 
 
 

An Assay Platform to Evaluate Cytokine Release & T Cell Activation

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

 
 
 

Expanding Healthcare Services with Digital Agreement Technology

Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

 
 
 

Revealing better ways to do business with agile analytics

Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members

 
 
 

Discover resources to support growth and innovation

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

 
 
 

Medical Affairs Metamorphosis, Part III: How Medical Affairs is Becoming a Key Hub for Evidence Generation

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

 
 
 

Plan for scalable process liquid and buffer preparation

Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation.

 
 
 

Reduce control arm sizes by up to 22% for HD & ALS RCTs

TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases.

 
 
 
 
 

Events